Edition:
United States

Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

4.13USD
3:58pm EDT
Change (% chg)

$0.03 (+0.73%)
Prev Close
$4.10
Open
$4.12
Day's High
$4.17
Day's Low
$4.07
Volume
1,860
Avg. Vol
11,400
52-wk High
$7.49
52-wk Low
$3.20

Select another date:

Wed, Sep 13 2017

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

BRIEF-Agenus Inc Q2 loss per share $0.32

* Agenus reports second quarter 2017 financial results and provides corporate update

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

Select another date: